Week 3 - L5 - Advanced Genotyping Assays: RFLP, ASO, and Microarray Technologies

Mechanism of Restriction Fragment Length Polymorphisms (RFLPs)

• Definition and Basic Concept

  • Restriction Fragment Length Polymorphisms (RFLPs) are a type of genotyping assay based on the ability of small genetic variants, such as Single Nucleotide Variants ($SNVs$) or insertions/deletions ($indels$), to coincidentally alter the recognition site of a restriction enzyme.

  • A restriction enzyme recognizes and cuts DNA at a specific, often palindromic, sequence. For example, the enzyme $HindIII$ recognizes and cleaves the sequence $AAGCTT$.

  • If a point mutation occurs within this recognition sequence (e.g., a change from $C$ to $G$), the enzyme will no longer recognize or cut the DNA at that specific locus.

• DNA Morphs and Fragmentation

  • The presence or absence of a restriction site creates different versions of the DNA region, referred to as "DNA morphs."

  • Morph 1 (Site Present): If the restriction site is intact, the enzyme cleaves the DNA. In a specific locus with multiple sites, this might result in multiple fragments (e.g., three cut sites producing two visible fragments in a specific region).

  • Morph 2 (Site Absent): If the mutation has eliminated the site, the enzyme fails to cut. Following digestion, this results in a single, larger fragment across the same region where Morph 1 would have produced two smaller ones.

Methodological Approaches to RFLP Analysis

• The Genomic Digest Problem

  • Genomic DNA contains thousands of restriction sites distributed throughout the genome. Digesting total genomic DNA with an enzyme results in so many fragments that they cannot be distinguished on a gel, appearing instead as a continuous "smear."

  • To resolve this, specific regions containing the polymorphism must be targeted using one of two primary methods: PCR-based RFLP or Probe-based RFLP.

• PCR-Based RFLP Analysis

  • PCR primers are designed to flank the region containing the potential restriction site. One primer fires into the region from one side, and the second primer fires from the other side.

  • The specific region is amplified, then treated with the restriction enzyme, and the products are visualized on an electrophoresis gel.

  • Genotype Interpretation:

    • Homozygous Morph 1: Displays only the smaller digested fragments (e.g., $2$ bands).

    • Homozygous Morph 2: Displays only the single, undigested larger fragment ($1$ band).

    • Heterozygous: Displays a combination of all fragments: the single large band from one chromosome and the two smaller bands from the other chromosome.

• Probe-Based RFLP (Traditional Method)

  • This older method involves digesting the entire genomic DNA with a restriction enzyme and transferring the fragments onto a membrane.

  • A labeled DNA probe—typically a short sequence complementary to the region containing the restriction site—is added.

  • The probe hybridizes specifically to the fragments of interest. If the site was present, the probe might bind to both smaller fragments (if it spans the cut site); if absent, it binds to the single large fragment.

Clinical RFLP Case Study: Sickle Cell Anemia

• Molecular Basis

  • Sickle cell anemia involves a variant in the beta-globin gene.

  • The non-pathogenic allele ($B^A$) contains the sequence $GAG$, which is recognized and cut by the restriction enzyme $MstII$ (or $MST$).

  • The pathogenic allele ($S$) contains a point mutation, changing the sequence to $GTG$. This mutation removes the $MstII$ recognition site.

• Genotyping Outcomes

  • Affected Individuals (Homozygous Pathogenic): The $MST$ site is absent. On a gel, this shows as a single large band because the DNA remains uncut by the enzyme at that locus.

  • Non-Pathogenic Individuals (Homozygous Reference): The $MST$ site is present. The DNA is cleaved, resulting in two smaller bands on the gel.

  • Carriers (Heterozygotes): These individuals possess one copy of each allele. The result is a triple-band pattern: the single large uncut band and the two smaller cut fragments.

Limitations of RFLP Genotyping

• Randomness of Sites: Most pathogenic variants do not happen to fall within a known restriction enzyme recognition site. The utility of RFLP is limited by the chance occurrence of the variant changing a cut site.

• Throughput and Complexity: RFLP is not high-throughput. Different variants require different restriction enzymes, and coordinating multiple digests for diverse markers is complex and inefficient.

Allele Specific Oligonucleotide (ASO) Assays

• Principles of Probe Hybridization

  • ASO assays utilize labeled "oligonucleotides," which are short stretches of synthetic DNA (often tagged with fluorescent markers).

  • The assay relies on the physical properties of DNA base-pairing. A probe is designed to be perfectly complementary to a specific allele (e.g., the reference allele).

  • The Mismatch Effect: If the probe encounters a target sequence with a Single Nucleotide Variant ($SNV$), a mismatch occurs (e.g., at base $11$ of the probe). This mismatch reduces the number of hydrogen bonds between the probe and the target strand.

  • Temperature Control: By raising the temperature to a precise threshold, probes with a mismatch will dissociate from the target, while perfectly complementary probes remain bound. The strength of the resulting signal (e.g., fluorescence) indicates whether the target allele is present.

• Application in Sickle Cell Anemia

  • A set of ASO probes can target Codon $6$ of the beta-globin gene, where the $A$ to $T$ substitution occurs.

  • Wild-type Probe (Reference): Returns a strong signal for homozygous reference ($AA$), a medium (half) signal for heterozygotes ($AS$), and no signal for homozygous pathogenic ($SS$).

  • Pathogenic Probe (Variant): Returns no signal for $AA$, a medium signal for $AS$, and a strong signal for $SS$.

• Application in Cystic Fibrosis ($\Delta 508$)

  • ASO assays can detect indels, such as the common $\Delta 508$ deletion (the loss of $3$ base pairs) in cystic fibrosis.

  • One probe is designed for the functional reference sequence, and another for the variant lacking those $3$ bases.

  • Affected Individuals: Highly strong binding for the $\Delta 508$ variant probe and zero binding for the reference probe.

  • Carriers: Binding detected for both the reference and the variant probes.

  • Non-Carriers: Binding detected only for the reference probe.

Advanced Genotyping and High-Throughput Microarrays

• Multi-Locus and Multi-Gene Analysis

  • Probes can be designed to genotype every base at a specific location. For example, in the $p53$ gene (a master regulator of DNA repair frequently mutated in cancers), four probes could be used to test for $A$, $C$, $T$, or $G$ at a single position to determine the exact sequence.

• Microarrays (Gene Chips)

  • Microarrays allow for the simultaneous analysis of thousands of alleles across multiple genes.

  • A microarray consists of a chip where each specific "spot" contains a unique probe for a specific allele (e.g., a spot for $TGCA$). The level of hybridization/binding at each coordinate indicates the presence of that specific variant in the sample.

• Validation Standards

  • While microarrays and probe assays are powerful for screening, any discovery of a pathogenic allele must be verified using independent methods.

  • The Gold Standard: DNA sequencing is considered the gold standard for confirmation. It is necessary to rule out false results (e.g., a probe failing to bind for reasons other than the targeted variant) and to ensure the exact nature of the pathogenic variant is correctly identified before making clinical conclusions.